Calypte Nominates Dian J. Harrison to Board of Directors; Planned Parenthood Golden Gate CEO Brings Wealth of Experience Promoting Health Issues Vital to Calypte's Cause.

Business Editors/Medical Writers

BIOWIRE2K

ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 3, 2002

Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot supplemental test, today announced that Dian J. Harrison, age 54, has agreed to join Calypte's board of directors. She has received unanimous approval from Calypte's current board and becomes a nominee, subject to shareholder approval, for Calypte's 2003 board of directors as part of the preliminary proxy filing of November 2002.

Ms. Harrison brings nearly 30 years of progressive experience in the healthcare and nonprofit sector to Calypte's board of directors. She currently serves as the president and chief executive officer of Planned Parenthood Golden Gate (PPGG), which serves the entire San Francisco Bay Area. PPGG is one of the largest Planned Parenthood affiliates in the United States. Harrison brought PPGG to fruition by merging Planned Parenthood Association of San Mateo County with Planned Parenthood affiliates in Alameda, San Francisco, Marin, Sonoma and Mendocino counties. She now leads and oversees the operations for nine health centers, a 300 staff organization and manages a $18 million annual operating budget. She is also the primary spokesperson for the organization in a variety of areas, including Medical Services, Education Programs, Advocacy, and Patient Rights.

"Dian brings to Calypte's board an extensive track record educating and administering care in reproductive and general health issues," stated Nancy Katz, president and CEO of Calypte. "While her credentials speak for themselves, it is Dian's passion for and involvement in community health that has propelled her career. Dian's community-based experience can help Calypte to increase the awareness of urine screening for HIV. We believe she will be a tremendous asset to our board."

Ms. Harrison currently serves on the board of the California Family Health Council. She has served on the boards of several organizations, including the American Civil Liberties Union (ACLU), the National Association for the Advancement of Colored People (NAACP) and the Red Rock Foundation. She received the Woman of the Year Award and the Women of Color Inspiration Award in 1996 from the National Women's Political Caucus, and was presented the 1997 Outstanding Leadership and Service Award from the Black Women for Political Action.

Prior to her work with Planned Parenthood, Harrison served in leadership positions with high-profile organizations such as the United Way, the Urban League, and Fisk University. She received an undergraduate degree in Sociology from California State University, Los Angeles, and a Masters Degree in Social Work Planning and Administration from Western Michigan University.

About Calypte Biomedical

Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot test. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Refer to current product package inserts for complete information on product performance characteristics.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue and expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K/A (No.1) for the year ended December 31, 2001 and its subsequent filings with the SEC.